“It is likely that the remediation by Celltrion of the issues addressed in the warning letter will result in a delayed approval of the biosimilar products by the FDA,” Teva told investors.
In Teva’s 2017 full-year and fourth-quarter financial results report, the company acknowledged that it is facing a substantial setback after its Republic of Korea-based partner, Celltrion, received a warning letter from the FDA that raised issues related to manufacturing.
“Celltrion is our sole source for [active pharmaceutical ingredient, API] production for fremanezumab and also for Celltrion’s products CT-P10 [biosimilar rituximab] and CT-P6 [biosimilar trastuzumab],” said Teva in its earnings report, adding that “It is likely that the remediation by Celltrion of the issues addressed in the warning letter will result in a delayed approval of the biosimilar products by the FDA.” Teva assured investors that “We are in active dialogue with the FDA in an effort to maintain our priority date for the approval of fremanezumab.”
Fremanezumab is Teva’s monoclonal antibody for the preventive treatment of migraine. The company submitted a Biologics License Application for the product to the FDA in December 2017. Teva had hopes of launching the innovative biologic in 2018.
However, Fierce Pharma reports that Teva’s CEO, Kare Schultz, said that “It could take 6 to 18 months to resolve a warning letter, but we are having [the active pharmaceutical ingredient] API made there and that is not affected by the warning letter, so an approval could be sooner, but we don’t know.” Shultz added that the warning letter addressed problems associated with the finished products portion of the plant, and not the production area.
The letter, recently released in full by the FDA, cites Celltrion’s failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes. It also says that Celltrion failed to thoroughly investigate any unexplained discrepancy in its products’ vials, or to investigate visible particles in finished drug products.
The news comes at an already tumultuous time for Israel-based Teva and for Shultz, who is leading the company through a 2-year streamlining process that includes laying off 25% of Teva's workforce and closing manufacturing and research and development sites worldwide.
Teva's stock dropped by 10.6% on Thursday, and by another 4.5% Friday morning.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.